CRSP
Price
$51.11
Change
-$1.08 (-2.07%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
4.97B
96 days until earnings call
Intraday BUY SELL Signals
FATE
Price
$0.98
Change
-$0.06 (-5.77%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
119.94M
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs FATE

Header iconCRSP vs FATE Comparison
Open Charts CRSP vs FATEBanner chart's image
CRISPR Therapeutics AG
Price$51.11
Change-$1.08 (-2.07%)
Volume$123.74K
Capitalization4.97B
Fate Therapeutics
Price$0.98
Change-$0.06 (-5.77%)
Volume$113.59K
Capitalization119.94M
CRSP vs FATE Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. FATE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CRSP: $52.19 vs. FATE: $1.04)
Brand notoriety: CRSP and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 108% vs. FATE: 84%
Market capitalization -- CRSP: $4.97B vs. FATE: $119.94M
CRSP [@Biotechnology] is valued at $4.97B. FATE’s [@Biotechnology] market capitalization is $119.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • FATE’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -8.42% price change this week, while FATE (@Biotechnology) price change was -4.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 17, 2026.

FATE is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.97B) has a higher market cap than FATE($120M). CRSP YTD gains are higher at: 32.597 vs. FATE (-36.970). FATE has higher annual earnings (EBITDA): -161.6M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. FATE (223M). FATE has less debt than CRSP: FATE (81.3M) vs CRSP (215M). CRSP has higher revenues than FATE: CRSP (35M) vs FATE (8.47M).
CRSPFATECRSP / FATE
Capitalization4.97B120M4,145%
EBITDA-533.5M-161.6M330%
Gain YTD32.597-36.970-88%
P/E RatioN/AN/A-
Revenue35M8.47M413%
Total Cash1.72B223M772%
Total Debt215M81.3M264%
FUNDAMENTALS RATINGS
CRSP vs FATE: Fundamental Ratings
CRSP
FATE
OUTLOOK RATING
1..100
5856
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
6065
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for CRSP (71). This means that FATE’s stock grew somewhat faster than CRSP’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that FATE’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (95) in the Biotechnology industry is in the same range as FATE (97). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

CRSP's Price Growth Rating (60) in the Biotechnology industry is in the same range as FATE (65). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

CRSP's P/E Growth Rating (71) in the Biotechnology industry is in the same range as FATE (100). This means that CRSP’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 21 days ago
80%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
FATE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NFFFX98.430.44
+0.45%
American Funds New World F2
LMUSX28.410.07
+0.25%
Franklin U.S. Large Cap Equity FI
SCJAX8.210.01
+0.12%
Steward Covered Call Income A
CHTVX24.900.02
+0.08%
Invesco Charter R5
MSMFX15.87N/A
N/A
Morgan Stanley Inst Discovery C

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-5.47%
BEAM - CRSP
70%
Closely correlated
-2.71%
RXRX - CRSP
68%
Closely correlated
-1.27%
PRME - CRSP
61%
Loosely correlated
-9.44%
CRBU - CRSP
61%
Loosely correlated
+0.89%
NTLA - CRSP
59%
Loosely correlated
-6.78%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CRBU. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-7.14%
CRBU - FATE
49%
Loosely correlated
+0.89%
RXRX - FATE
49%
Loosely correlated
-1.27%
IPSC - FATE
48%
Loosely correlated
N/A
CRSP - FATE
48%
Loosely correlated
-5.47%
ALLO - FATE
46%
Loosely correlated
-0.81%
More